Stoke Therapeutics (NASDAQ:STOK) Releases Quarterly Earnings Results

Stoke Therapeutics (NASDAQ:STOK) announced its quarterly earnings results on Thursday. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.15), FiscalAI reports. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. The business had revenue of $11.26 million during the quarter, compared to the consensus estimate of $8.21 million.

Here are the key takeaways from Stoke Therapeutics’ conference call:

• EMPEROR Phase III remains on track: Approximately 110 of 162 patients have reached the week 28 primary endpoint visit, about 20 have completed the 52-week treatment period, and no patients have discontinued treatment. Stoke continues to expect topline data in Q3 2027.
• The FDA agreed that Stoke may use a multicomponent Vineland-3 assessment covering four cognitive and behavioral subdomains for the planned U.S. NDA. Management believes this approach better reflects Dravet syndrome’s variability and improves statistical power; the company does not currently anticipate an advisory committee meeting.
• Stoke is advancing its potential commercial launch of zorevunersen, estimating approximately 6,000 immediately addressable U.S. pediatric patients and increasing awareness among treatment centers, payers, and neurologists. The company is preparing patient services, market access, and treatment-site infrastructure for a potential launch in early 2028.
• The STK-002 program for autosomal dominant optic atrophy is progressing, with dosing underway in the third OSPREY cohort and a fourth cohort expected to begin in early 2027. Initial safety and efficacy data from higher-dose cohorts are anticipated in the first half of 2027.
• Stoke ended the quarter with $358.8 million in cash, cash equivalents, and marketable securities, while reporting a quarterly net loss of $73.6 million. Including expected Biogen reimbursements and a potential development milestone, management expects its cash position to fund operations into early 2028.

Stoke Therapeutics Stock Down 0.2%

Shares of NASDAQ:STOK traded down $0.06 during mid-day trading on Thursday, reaching $26.35. 1,879,613 shares of the stock were exchanged, compared to its average volume of 1,162,655. The stock’s 50 day simple moving average is $27.53 and its 200-day simple moving average is $30.90. Stoke Therapeutics has a one year low of $20.32 and a one year high of $40.22.

Analysts Set New Price Targets

STOK has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. JPMorgan Chase & Co. initiated coverage on shares of Stoke Therapeutics in a research note on Friday, August 21st. They issued an “overweight” rating and a $40.00 price target on the stock. Canaccord Genuity Group reduced their price target on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of Stoke Therapeutics in a report on Thursday, September 10th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $44.25.

Insider Activity

In other news, General Counsel Jonathan Allan sold 2,861 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $91,637.83. Following the sale, the general counsel owned 21,225 shares of the company’s stock, valued at $679,836.75. The trade was a 11.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 1,051 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $26.16, for a total transaction of $27,494.16. Following the transaction, the insider owned 19,059 shares of the company’s stock, valued at $498,583.44. The trade was a 5.23% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 34,594 shares of company stock worth $1,069,305 over the last ninety days. Insiders own 9.60% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.